XXIIHIGH SIGNALFINANCIAL10-K

XXII executed a dramatic financial restructuring with an 89% debt reduction and 293% equity increase, while shares outstanding plummeted 72% from 2.37M to 662K shares.

The massive reduction in share count combined with debt paydown and equity infusion suggests either a major reverse stock split, significant dilutive equity raise followed by share buybacks, or a complex restructuring transaction. The removal of litigation risk language and improved operational metrics indicate the company may have resolved major legal issues and is repositioning for growth.

Comparing 2026-03-26 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

XXII underwent a complete financial transformation with total debt slashed from $6.7M to $708K while stockholders' equity surged 293% to $15.8M, indicating either debt-to-equity conversion or fresh capital injection. Operational improvements are evident with the company moving to gross profitability ($14K vs -$21K loss) and cutting net losses by two-thirds to $5.1M, while working capital strengthened across inventory (+115%) and receivables (+112%). The 2,553% spike in interest expense despite lower debt levels suggests either one-time debt restructuring costs or significantly higher rates on remaining obligations, but the overall picture signals a company that has successfully recapitalized and is gaining operational traction.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+2553.3%
$353K$9.4M

Interest expense surged 2553.3% — significant debt increase or rising rates materially impacting earnings.

Stockholders Equity
Balance Sheet
+292.8%
$4.0M$15.8M

Equity base grew 292.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Gross Profit
P&L
+168.6%
-$21K$14K

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Inventory
Balance Sheet
+114.7%
$2.0M$4.3M

Inventory surged 114.7% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Accounts Receivable
Balance Sheet
+111.7%
$1.7M$3.6M

Receivables surged 111.7% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Debt
Balance Sheet
-89.4%
$6.7M$708K

Debt reduced 89.4% — deleveraging strengthens balance sheet and reduces financial risk.

Net Income
P&L
+66.7%
-$15.2M-$5.1M

Net income grew 66.7% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
+61.7%
$4.4M$7.1M

Cash position surged 61.7% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
-56.7%
$141K$61K

Capex reduced 56.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
+53%
$11.5M$17.6M

Current assets grew 53% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-20
ADDED
On March 20, 2026, the registrant had 662,023 shares of common stock issued and outstanding.
We may be unsuccessful at commercializing our Reduced Nicotine Content (RNC) tobacco and the VLN brand RNC cigarettes using the reduced exposure claims authorized by the Food and Drug Administration (FDA).
The States or National Association of Attorneys General (NAAG) may not approve our products in certain states which, could have an adverse impact on our results of operations.
Unless the context otherwise requires, references to the Company, 22 nd Century, we, us, and our refer to 22nd Century Group, Inc., a Nevada corporation, and its subsidiaries.
is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes.
+7 more — sign up free →
REMOVED
On March 17, 2025, the registrant had 2,369,552 shares of common stock issued and outstanding.
Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of December 31, 2024.
We may be unsuccessful at commercializing our Reduced Nicotine Content (RNC) tobacco and the RNC cigarette brand, VLN , using the reduced exposure claims authorized by the Food and Drug Administration (FDA).
The States or NAAG may not approve our products in certain states which could have an adverse impact on our results of operations.
We are a named defendant in certain litigation matters; if we are unable to resolve these matters favorably, then our business, operating results and financial condition may be adversely affected.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →